The US FDA has granted Fast-Track Designation to the groundbreaking antimicrobial peptide OMN6 from Israel’s Omnix Medical (see here previously). OMN6 is commencing a Phase II trial in patients with two deadly hospital-acquired pneumonias – HABP and VABP. https://omnixmedical.com/2024/02/20/omnix-medical-granted-fast-track-designation-by-u-s-fda-for-its-next-generation-anti-infective-omn6/

Israel’s Omnix (reported here previously) has been awarded €10.8 million in EU funding under the EIC Accelerator Programme, part of the EU’s Horizon 2020 research funding program. Omnix’s OMN6 peptide destroys the bacteria’s membrane, regardless of its resistance. https://www.calcalistech.com/ctech/articles/0,7340,L-3889749,00.html https://www.omnixmedical.com/omnix-medical-wins-e10-8m-in-eic-accelerator-funding/

Israel’s Omnix Medical (reported here previously( is developing novel antibiotic agents for the treatment of hospital-acquired infections involving resistant bacteria. Omnix has successfully completed lab testing and has now raised funding to allow it to commence human clinical trials. https://www.calcalistech.com/ctech/articles/0,7340,L-3868294,00.html … Continue reading →

Six Israeli bio-techs pitched their therapies to investors at the Azrieli College of Engineering. Concenter (type-2 diabetes treatment), Omnysense (hi-tech thermometer), Omnix (antibiotic), Neurogenesis (neuron injections), Vaxil (anti-cancer vaccine) and Virucure (anti-cancer virus). https://baltimorejewishlife.com/news/news-detail.php?SECTION_ID=37&ARTICLE_ID=120531